Organogenesis Inc. is Recipient of a 'Best of Biotech' Award.
CANTON, Mass.--(BW HealthWire)--Dec. 7, 2000
Organogenesis Inc. (AMEX:ORG) today announced its receipt of a Best of Biotech award for the Company's achievement of the product Apligraf(R) for the treatment of diabetic foot ulcers. Award selection was based on the voting of biotechnology chief executive officers - business leaders in the industry.
Apligraf is the first, and only, mass-produced product containing living human cells to prove efficacy and gain FDA marketing approval. In June 2000, Apligraf was approved for use in diabetic foot ulcers; the product was previously approved for use in venous leg ulcers. The development of Apligraf has required state-of-the-art expertise in many disciplines, including mammalian cell culture, cellular differentiation and immunology.
Leading the Company's research program is Nancy Parenteau, Ph.D., Chief Scientific Officer and Senior Vice President, Research and Development, a world leader in tissue engineering. In addition to her many scientific publications, book chapters and presentations, Dr. Parenteau serves by invitation on key organizations involved in shaping the future of the field. She recently served as a panel member for the prestigious World Technology Evaluation (WTEC) Study on Tissue Engineering commissioned by several governmental agencies including the National Science Foundation, US Food and Drug Administration, National Institutes of Health, the Department of Commerce and the Department of Defense. Dr. Parenteau is also a member of the federal National Research Council's Chemical Sciences Roundtable and is on the Board of the Pittsburgh Tissue Engineering Initiative.
The Company's clinical and regulatory programs are under the leadership of Michael Sabolinski, M.D., Senior Vice President, Medical and Regulatory Affairs. In addition to achieving the only FDA approvals in the field for a mass-produced product containing living human cells, Dr. Sabolinski presents frequently at national and international conferences on wound-healing and has a number of clinical publications in the field. Dr. Sabolinski accepted the Award on behalf of Organogenesis at the 13th annual biotechnology CEO meeting in Laguna Niguel, California.
"We are proud of our state-of-the-art tissue engineering expertise," said Philip Laughlin, President and Chief Executive Officer. "We are pleased to now be gaining recognition not only in the scientific and medical communities, but also in the business community. We are applying this expertise to bringing other exciting products to market."
The Company's product development focus includes living tissue replacements, cell-based organ assist devices and other tissue-engineered products. Apligraf is a cellular, bi-layered skin substitute; Novartis Pharma AG has global Apligraf marketing rights. The Organogenesis research pipeline includes the VITRIX(TM) living dermal replacement product, a coronary vascular graft and a liver assist device.
Apligraf(R) is a registered trademark of Novartis.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 7, 2000|
|Previous Article:||HMSHost Celebrates Opening of Its Newest Food Court At Beckley, West Virginia Travel Plaza.|
|Next Article:||Ice.com, Internet's No. 1 Jewelry Site, Returns to Montreal; Most-Trafficked Jeweler on the Web Moves Headquarters Back to Hometown.|